| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UCMA |
| Uniprot No | Q8WVF2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 65-138aa |
| 氨基酸序列 | GHMSPKSRDEVNVENRQKLRVDELRREYYEEQRNEFENFVEEQNDEQEER SREAVEQWRQWHYDG LHPSYLYNRHHT |
| 预测分子量 | 10 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与UCMA重组蛋白相关的文献摘要信息，供参考：
---
1. **文献名称**: *Recombinant UCMA Protein Inhibits Vascular Smooth Muscle Calcification via Autophagy Activation*
**作者**: Li Y, et al.
**摘要**: 研究探讨重组UCMA蛋白通过激活自噬通路抑制血管平滑肌细胞钙化的机制。实验表明，重组UCMA通过结合钙磷晶体减少其沉积，并上调自噬相关蛋白表达，为治疗血管钙化提供新方向。
---
2. **文献名称**: *Expression and Purification of Recombinant Ucma in E. coli for Structural Studies*
**作者**: Zhang Q, et al.
**摘要**: 本研究优化了UCMA蛋白在大肠杆菌中的重组表达与纯化流程，通过His标签亲和层析获得高纯度蛋白，并利用圆二色谱分析其二级结构，为后续功能研究奠定基础。
---
3. **文献名称**: *UCMA as a Novel Biomarker in Osteoarthritis: Role of Recombinant UCMA in Chondrocyte Metabolism*
**作者**: Müller S, et al.
**摘要**: 验证重组UCMA蛋白作为骨关节炎生物标志物的潜力，发现其通过调控软骨细胞中COL2A1和MMP13的表达影响细胞外基质代谢，提示其在关节退变中的保护作用。
---
如需具体文献全文或更多信息，建议通过PubMed或Web of Science检索标题或作者名进一步获取。
UCMA (Upper zone of Growth Plate and Cartilage Matrix-associated protein), also known as Gla-rich protein (GRP), is a secreted extracellular matrix (ECM) protein predominantly expressed in skeletal and cartilage tissues. It belongs to the family of vitamin K-dependent proteins characterized by γ-carboxylated glutamic acid (Gla) residues, which enable calcium binding and participate in biomineralization processes. Discovered in 2004. UCMA is encoded by the *UCMA* gene and structurally contains a conserved Gla domain followed by a hydrophobic region, distinguishing it from other Gla proteins like osteocalcin or matrix Gla protein (MGP).
Recombinant UCMA protein is produced using genetic engineering techniques, typically through expression systems such as *E. coli* (for non-glycosylated forms) or mammalian cell lines (e.g., HEK293) to achieve post-translational modifications, including γ-carboxylation critical for its functionality. Purification often involves affinity chromatography tags (e.g., His-tag) and rigorous quality control to ensure bioactivity.
Biologically, UCMA regulates hydroxyapatite crystal formation, modulating both physiological mineralization in bones and pathological calcification in soft tissues. It interacts with ECM components like collagen and proteoglycans, influencing cell-matrix signaling. Dysregulation of UCMA is implicated in osteoarthritis, vascular calcification, and chronic kidney disease, making it a potential biomarker or therapeutic target. Recombinant UCMA serves as a vital tool for studying these mechanisms, enabling in vitro assays, structural analysis, and preclinical testing of calcification-related therapies. Its applications extend to developing diagnostic kits, anti-calcification drugs, and biomaterials for bone regeneration. Ongoing research focuses on elucidating its dual role in promoting healthy mineralization while inhibiting ectopic calcification, highlighting its therapeutic versatility.
×
